Tag: antisense and rnai therapeutics market size

Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.

Antisense & RNAi Therapeutics Market Revenue Outlook: What CAGR Lies Ahead Through 2030?

The antisense & rnai therapeutics market size has seen swift expansion in recent years. It is projected to increase from $1.93 billion in 2025 to $2.17 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 12.6%. The historical growth can be attributed to the early adoption of antisense therapies, initial rnai research breakthroughs, the development of oligonucleotide synthesis techniques, increasing demand for targeted therapeutics, and investments in biotech research.

The antisense & rnai therapeutics market size is projected to experience rapid growth in the upcoming years. It is forecast to grow to $3.53 billion in 2030, achieving a compound annual growth rate (CAGR) of 12.9%. This expansion during the forecast period can be attributed to advancements in delivery technologies, the broadening scope of precision medicine, integration with AI-driven drug discovery, an increase in RNAi-based clinical trials, and rising healthcare investments in emerging markets. Major trends expected in this period include targeted gene silencing, novel delivery mechanisms, personalized therapeutics, nucleic acid stabilization techniques, and ongoing regulatory & clinical advancements.

Get A Free Sample Report With In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3389&type=smp&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Antisense & RNAi Therapeutics Market Growth Catalysts And Demand Drivers

The increasing occurrence of coronary artery diseases, neurodegenerative conditions, and infectious diseases is anticipated to fuel the demand for the antisense & RNAi therapeutics market. Gene suppression methods, such as RNA interference and antisense oligonucleotides, find application in treating numerous neurodegenerative conditions through the repair of mutant genes. As an illustration, a report released in January 2024 by the American Heart Association, an organization based in the US, indicated that the age-adjusted death rate attributed to cardiovascular diseases climbed to 233.3 per 100,000, which represented a 4.0% increase compared to the prior year. Consequently, the expanding prevalence of various neurodegenerative diseases and infectious diseases is foreseen to stimulate the expansion of the antisense & RNAi therapeutics market.

Antisense & RNAi Therapeutics Market Segment Landscape: Which Areas Lead Development?

The antisense & rnai therapeutics market covered in this report is segmented –

1) By Technology: RNA Interference, Antisense RNA

2) By Route Of Administration: Intravenous Injections, Intra-dermal Injections, Other Delivery Methods

3) By Indication: Oncology, Cardiovascular Diseases (CVDs), Respiratory Disorders, Neurological Disorders, Infectious Diseases, Other Indications

Subsegments:

1) By RNA Interference (RNAi): Small Interfering RNA (siRNA), Short Hairpin RNA (shRNA), Dicer-substrate siRNA, MicroRNA (miRNA) Based Therapeutics

2) By Antisense RNA: Antisense Oligonucleotides (ASOs), Morpholino Oligomers, Locked Nucleic Acids (LNAs), Gapmer Antisense Oligonucleotides

Antisense & RNAi Therapeutics Market Trends Shaping Long-Term Demand

Leading companies in the antisense & RNAi therapeutics market are pursuing strategic initiatives, including collaborations and partnerships, to thrive in the increasingly competitive landscape. A strategic collaboration represents a business approach where two or more entities work together towards a common goal or objective. For example, in January 2023, Orbit Discovery Limited, a US-based firm providing peptide discovery services, entered into a partnership with SanegeneBio Inc., a UK-based company developing novel RNAi-based medicines. This partnership aimed to identify tissue-specific delivery of RNA therapeutics for efficient gene knockdown, with the objective of developing a portfolio of advanced RNAi therapeutics. The collaboration involves hit identification and cell-based internalization studies, granting Sanegene the option to further develop the hits identified from screening activities, by leveraging Orbit’s proprietary technology for rapid peptide lead discovery. Orbit Discovery’s unique peptide display engine allows for the screening of large peptide libraries, leading to faster discovery times for relevant peptide leads based on affinity and functional screens.

Antisense & RNAi Therapeutics Market Industry Leaders And Competitive Landscape

Major companies operating in the antisense & rnai therapeutics market are Biogen Inc., Ionis Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Moderna Inc., Sanofi S.A., Dicerna Pharmaceuticals Inc., Arbutus Biopharma Corporation, Acuitas Therapeutics, Adhera Therapeutics Inc., EdiGene Inc., Sirnaomics Inc., Suzhou Ribo Life Science Co. Ltd, Biocon Limited, Quark Pharmaceuticals, GlaxoSmithKline Plc, Shanghai Junshi Biosciences Co. Ltd., AstraZeneca, Benitec Biopharma Limited, Silence Therapeutics, Dynacure, CN Bio Innovations, Sarepta Therapeutics, Mallinckrodt, Regeneron Pharmaceuticals Inc., Alcyone Lifesciences Inc., Bio-Path Holdings Inc, Calando Pharmaceuticals, Enzon Pharmaceuticals Inc, Celnova Pharma, Pfizer Inc., Taiba Pharma, Gen İlaç ve Sağlık Ürünleri A.Ş., Egypt Otsuka Pharmaceutical

View The Full Antisense & RNAi Therapeutics Market Report:

https://www.thebusinessresearchcompany.com/report/antisense-and-rnai-therapeutics-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Antisense & RNAi Therapeutics Market Regional Analysis: Which Geography Leads On Revenue?

North America was the largest region in the antisense & RNAi therapeutics market in 2025. The regions covered in the antisense & rnai therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

Antisense & RNAi Therapeutics Market Value Expansion And Long-Term Growth Outlook

The antisense and RNAi therapeutics market has experienced significant expansion over the past few years. Its size is projected to increase from $1.93 billion in 2025 to $2.17 billion in 2026, reflecting a compound annual growth rate (CAGR) of 12.6%. This historical growth has been driven by the early application of antisense treatments, pioneering advances in RNAi research, improvements in oligonucleotide synthesis methods, a rising need for targeted therapies, and increased funding for biotechnology investigations.

The market for antisense and RNAi therapeutics is projected to experience rapid expansion over the coming years. Its value is anticipated to reach $3.53 billion by 2030, achieving a compound annual growth rate (CAGR) of 12.9%. During this forecast period, growth is fueled by progress in delivery technologies, the broadening of precision medicine, the incorporation of AI into drug discovery, a higher number of RNAi-focused clinical trials, and increased healthcare spending in developing regions. Key developments shaping this period feature targeted gene silencing, innovative delivery approaches, customized treatments, methods for stabilizing nucleic acids, and improvements in regulatory and clinical frameworks.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3389&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Antisense & RNAi Therapeutics Market Growth Drivers: What Factors Are Accelerating Expansion?

The increasing incidence of coronary artery diseases, neurodegenerative disorders, and infectious conditions is anticipated to boost demand within the antisense and RNAi therapeutics market. By repairing defective genes, gene suppression methods such as RNA interference and antisense oligonucleotides are applied to manage a range of neurodegenerative diseases. In January 2024, for example, the American Heart Association, a US-based organization, reported that the age-adjusted death rate from cardiovascular illnesses had risen to 233.3 per 100,000 individuals, marking a 4.0% increase compared to the prior year. Consequently, the escalating occurrence of multiple neurodegenerative and infectious ailments is expected to propel the expansion of the antisense and RNAi therapeutics market.

Antisense & RNAi Therapeutics Market Segment Outlook: Which Categories Are Expanding The Fastest?

The antisense & rnai therapeutics market covered in this report is segmented –

1) By Technology: RNA Interference, Antisense RNA

2) By Route Of Administration: Intravenous Injections, Intra-dermal Injections, Other Delivery Methods

3) By Indication: Oncology, Cardiovascular Diseases (CVDs), Respiratory Disorders, Neurological Disorders, Infectious Diseases, Other Indications

Subsegments:

1) By RNA Interference (RNAi): Small Interfering RNA (siRNA), Short Hairpin RNA (shRNA), Dicer-substrate siRNA, MicroRNA (miRNA) Based Therapeutics

2) By Antisense RNA: Antisense Oligonucleotides (ASOs), Morpholino Oligomers, Locked Nucleic Acids (LNAs), Gapmer Antisense Oligonucleotides

Antisense & RNAi Therapeutics Market Trends: What Is Shaping Future Industry Growth?

Major players in the antisense and RNAi therapeutics space are adopting proactive strategies like collaborations and partnerships to maintain their competitive position. A strategic collaboration is defined as an arrangement where two or more firms join forces to pursue a shared objective. As an example, in January 2023, Orbit Discovery Limited, an American company specializing in peptide discovery services, formed a partnership with SanegeneBio Inc., a British organization focused on creating novel RNAi-based treatments. This alliance aims to identify tissue-specific delivery mechanisms for RNA therapeutics to achieve effective gene knockdown, with the ultimate goal of building a strong pipeline of advanced RNAi treatments. The agreement covers hit identification and cell-based internalization studies, and Sanegene retains the option to further develop any promising hits resulting from the screening process. This is achieved by tapping into Orbit’s proprietary technology, which accelerates the discovery of peptide leads. Orbit Discovery’s distinctive peptide display platform allows for the screening of extensive peptide libraries, significantly reducing the time needed to find appropriate peptide leads based on affinity and functional assays.

Antisense & RNAi Therapeutics Market Key Companies And Competitive Benchmarking

Major companies operating in the antisense & rnai therapeutics market are Biogen Inc., Ionis Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Moderna Inc., Sanofi S.A., Dicerna Pharmaceuticals Inc., Arbutus Biopharma Corporation, Acuitas Therapeutics, Adhera Therapeutics Inc., EdiGene Inc., Sirnaomics Inc., Suzhou Ribo Life Science Co. Ltd, Biocon Limited, Quark Pharmaceuticals, GlaxoSmithKline Plc, Shanghai Junshi Biosciences Co. Ltd., AstraZeneca, Benitec Biopharma Limited, Silence Therapeutics, Dynacure, CN Bio Innovations, Sarepta Therapeutics, Mallinckrodt, Regeneron Pharmaceuticals Inc., Alcyone Lifesciences Inc., Bio-Path Holdings Inc, Calando Pharmaceuticals, Enzon Pharmaceuticals Inc, Celnova Pharma, Pfizer Inc., Taiba Pharma, Gen Ilaç ve Saglik Ürünleri A.S., Egypt Otsuka Pharmaceutical

Access The Complete Antisense & RNAi Therapeutics Market Report:

https://www.thebusinessresearchcompany.com/report/antisense-and-rnai-therapeutics-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Antisense & RNAi Therapeutics Market Regional Analysis And Leading Geography

North America was the largest region in the antisense & RNAi therapeutics market in 2025. The regions covered in the antisense & rnai therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Anticipated Rise In Market Value Of The Antisense & RNAi Therapeutics Market During The Forecast Period?

The antisense & rnai therapeutics market size has seen swift expansion in recent years. It is anticipated to increase from $1.93 billion in 2025 to $2.17 billion in 2026, representing a compound annual growth rate (CAGR) of 12.6%. The historical growth of this market is attributable to the early adoption of antisense therapies, initial rnai research breakthroughs, the progression of oligonucleotide synthesis techniques, a growing need for targeted therapeutics, and investments in biotech research.

The antisense & rnai therapeutics market size is anticipated to experience swift expansion over the coming years. It is projected to reach $3.53 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 12.9%. The expected growth within this forecast period is attributed to advancements in delivery technologies, the expanding field of precision medicine, integration with AI-driven drug discovery, an increase in RNAi-based clinical trials, and rising healthcare investments in emerging markets. Significant trends for the forecast period include targeted gene silencing, novel delivery mechanisms, personalized therapeutics, nucleic acid stabilization techniques, and progress in regulatory and clinical areas.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3389&type=smp

What Key Drivers Are Fueling The Growth Of The Antisense & RNAi Therapeutics Market?

The increasing incidence of coronary artery diseases, neurodegenerative disorders, and infectious diseases is expected to boost the demand for the antisense & RNAi therapeutics market. Gene suppression methods like RNA interference and antisense oligonucleotides are utilized to treat various neurodegenerative conditions by mending mutant genes. As an illustration, a January 2024 report by the American Heart Association, a US-based organization, stated that the age-adjusted death rate from cardiovascular diseases escalated to 233.3 per 100,000, marking a 4.0% increase from the previous year. Thus, the rising prevalence of several neurodegenerative and infectious diseases is anticipated to propel the growth of the antisense & RNAi therapeutics market.

How Is The Antisense & RNAi Therapeutics Market Broken Down By Segment Categories?

The antisense & rnai therapeutics market covered in this report is segmented –

1) By Technology: RNA Interference, Antisense RNA

2) By Route Of Administration: Intravenous Injections, Intra-dermal Injections, Other Delivery Methods

3) By Indication: Oncology, Cardiovascular Diseases (CVDs), Respiratory Disorders, Neurological Disorders, Infectious Diseases, Other Indications

Subsegments:

1) By RNA Interference (RNAi): Small Interfering RNA (siRNA), Short Hairpin RNA (shRNA), Dicer-substrate siRNA, MicroRNA (miRNA) Based Therapeutics

2) By Antisense RNA: Antisense Oligonucleotides (ASOs), Morpholino Oligomers, Locked Nucleic Acids (LNAs), Gapmer Antisense Oligonucleotides

What Trends Are Affecting The Direction Of The Antisense & RNAi Therapeutics Market?

Major companies operating in the antisense & RNAi therapeutics market are engaging in strategic initiatives, such as collaborations and partnerships, to sustain their presence in the increasingly competitive market. Strategic collaboration represents a business strategy that involves two or more companies working together to achieve a common goal or objective. For instance, in January 2023, Orbit Discovery Limited, a US-based company providing services for peptide discovery, partnered with SanegeneBio Inc., a UK-based company involved in developing novel RNAi-based medicines. This partnership aims at identifying tissue-specific delivery of RNA therapeutics for efficient gene knockdown, with the objective of developing a portfolio of advanced RNAi therapeutics. The collaboration includes hit identification and cell-based internalization studies, with Sanegene having the option to further develop the hits derived from the screening activities, leveraging Orbit’s proprietary technology for rapid peptide lead discovery. Orbit Discovery’s unique peptide display engine facilitates the screening of large peptide libraries, offering faster discovery times for relevant peptide leads based on affinity and functional screens.

Which Players Are Present In The Antisense & RNAi Therapeutics Market Space?

Major companies operating in the antisense & rnai therapeutics market are Biogen Inc., Ionis Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Moderna Inc., Sanofi S.A., Dicerna Pharmaceuticals Inc., Arbutus Biopharma Corporation, Acuitas Therapeutics, Adhera Therapeutics Inc., EdiGene Inc., Sirnaomics Inc., Suzhou Ribo Life Science Co. Ltd, Biocon Limited, Quark Pharmaceuticals, GlaxoSmithKline Plc, Shanghai Junshi Biosciences Co. Ltd., AstraZeneca, Benitec Biopharma Limited, Silence Therapeutics, Dynacure, CN Bio Innovations, Sarepta Therapeutics, Mallinckrodt, Regeneron Pharmaceuticals Inc., Alcyone Lifesciences Inc., Bio-Path Holdings Inc, Calando Pharmaceuticals, Enzon Pharmaceuticals Inc, Celnova Pharma, Pfizer Inc., Taiba Pharma, Gen İlaç ve Sağlık Ürünleri A.Ş., Egypt Otsuka Pharmaceutical

Get The Full Antisense & RNAi Therapeutics Market Report:

https://www.thebusinessresearchcompany.com/report/antisense-and-rnai-therapeutics-global-market-report

Which Region Accounts For The Largest Portion Of The Antisense & RNAi Therapeutics Market?

North America was the largest region in the antisense & RNAi therapeutics market in 2025. The regions covered in the antisense & rnai therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Antisense & RNAi Therapeutics Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/antisense-and-rnai-therapeutics-global-market-report

Browse Through More Reports Similar to the Global Antisense & RNAi Therapeutics Market 2026, By The Business Research Company

Antisense And Rnai Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/antisense-and-rnai-therapeutics-global-market-report

Rna Targeting Small Molecules Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/rna-targeting-small-molecules-therapeutics-global-market-report

Mrna Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/mrna-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Expansion Is Predicted For The Antisense & RNAi Therapeutics Market Between 2026 And 2030?

The antisense & rnai therapeutics market size has seen swift expansion in recent years. It is projected to increase from $1.93 billion in 2025 to $2.17 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 12.6%. This historical growth is attributable to the early adoption of antisense therapies, initial rnai research breakthroughs, the development of oligonucleotide synthesis techniques, growing demand for targeted therapeutics, and investments in biotech research.

The antisense & rnai therapeutics market is projected to experience substantial expansion over the coming years. This market is anticipated to reach $3.53 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 12.9%. Factors contributing to this growth during the forecast period include advances in delivery technologies, the broadening scope of precision medicine, integration with AI-driven drug discovery, a rise in RNAi-based clinical trials, and increased healthcare investments within emerging markets. Key trends expected during the same period encompass targeted gene silencing, innovative delivery mechanisms, personalized therapeutic approaches, nucleic acid stabilization techniques, and progress in regulatory and clinical aspects.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3389&type=smp

What Key Drivers Are Influencing The Growth Of The Antisense & RNAi Therapeutics Market?

The increasing incidence of coronary artery diseases, neurodegenerative conditions, and infectious ailments is anticipated to fuel the demand within the antisense & RNAi therapeutics market. Gene silencing methods, such as RNA interference and antisense oligonucleotides, find application in addressing diverse neurodegenerative diseases through the correction of faulty genes. For example, a report from January 2024 by the American Heart Association, a US-based organization, indicated that the age-adjusted mortality rate from cardiovascular diseases rose to 233.3 per 100,000, showing a 4.0% increase compared to the prior year. Consequently, the expanding occurrence of numerous neurodegenerative conditions and infectious illnesses is set to propel the expansion of the antisense & RNAi therapeutics market.

Which Market Segments Are Examined In The Antisense & RNAi Therapeutics Market Study?

The antisense & rnai therapeutics market covered in this report is segmented –

1) By Technology: RNA Interference, Antisense RNA

2) By Route Of Administration: Intravenous Injections, Intra-dermal Injections, Other Delivery Methods

3) By Indication: Oncology, Cardiovascular Diseases (CVDs), Respiratory Disorders, Neurological Disorders, Infectious Diseases, Other Indications

Subsegments:

1) By RNA Interference (RNAi): Small Interfering RNA (siRNA), Short Hairpin RNA (shRNA), Dicer-substrate siRNA, MicroRNA (miRNA) Based Therapeutics

2) By Antisense RNA: Antisense Oligonucleotides (ASOs), Morpholino Oligomers, Locked Nucleic Acids (LNAs), Gapmer Antisense Oligonucleotides

Which Trends Are Influencing The Antisense & RNAi Therapeutics Market?

Major companies operating in the antisense & RNAi therapeutics market are engaging in strategic initiatives, such as collaborations and partnerships, to sustain their presence in the increasingly competitive market. A strategic collaboration is a business approach where two or more companies work together to achieve a common goal or objective. For instance, in January 2023, Orbit Discovery Limited, a US-based company providing services for peptide discovery, partnered with SanegeneBio Inc., a UK-based company focused on developing novel RNAi-based medicines, to identify tissue-specific delivery of RNA therapeutics for efficient gene knockdown, with the aim of developing a portfolio of advanced RNAi therapeutics. This collaboration includes hit identification and cell-based internalization studies, granting Sanegene the option to further develop the hits derived from the screening activities, by leveraging Orbit’s proprietary technology for rapid peptide lead discovery. Orbit Discovery’s unique peptide display engine allows for the screening of large peptide libraries, leading to faster discovery times for relevant peptide leads based on affinity and functional screens.

Who Are The Primary Competitors In The Antisense & RNAi Therapeutics Market?

Major companies operating in the antisense & rnai therapeutics market are Biogen Inc., Ionis Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Moderna Inc., Sanofi S.A., Dicerna Pharmaceuticals Inc., Arbutus Biopharma Corporation, Acuitas Therapeutics, Adhera Therapeutics Inc., EdiGene Inc., Sirnaomics Inc., Suzhou Ribo Life Science Co. Ltd, Biocon Limited, Quark Pharmaceuticals, GlaxoSmithKline Plc, Shanghai Junshi Biosciences Co. Ltd., AstraZeneca, Benitec Biopharma Limited, Silence Therapeutics, Dynacure, CN Bio Innovations, Sarepta Therapeutics, Mallinckrodt, Regeneron Pharmaceuticals Inc., Alcyone Lifesciences Inc., Bio-Path Holdings Inc, Calando Pharmaceuticals, Enzon Pharmaceuticals Inc, Celnova Pharma, Pfizer Inc., Taiba Pharma, Gen İlaç ve Sağlık Ürünleri A.Ş., Egypt Otsuka Pharmaceutical

Read the full antisense & rnai therapeutics market report here:

https://www.thebusinessresearchcompany.com/report/antisense-and-rnai-therapeutics-global-market-report

Which Region Is Expected To Register The Fastest Growth In The Antisense & RNAi Therapeutics Market?

North America was the largest region in the antisense & RNAi therapeutics market in 2025. The regions covered in the antisense & rnai therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Antisense & RNAi Therapeutics Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=3389&type=smp

Browse Through More Reports Similar to the Global Antisense & RNAi Therapeutics Market 2026, By The Business Research Company

Antisense And Rnai Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/antisense-and-rnai-therapeutics-global-market-report

Rna Targeting Small Molecules Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/rna-targeting-small-molecules-therapeutics-global-market-report

Mrna Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/mrna-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the antisense & rnai therapeutics market from 2026–2035 with trusted insights from The Business Research Company

What growth pattern is forecast for the Antisense & RNAi Therapeutics Market size between 2026 and 2035?

The antisense & rnai therapeutics market size has observed substantial growth in recent years. It is forecast to rise from $1.93 billion in 2025 to $2.17 billion in 2026, reflecting a compound annual growth rate (CAGR) of 12.6%. The expansion witnessed in previous periods is attributable to factors such as the early adoption of antisense therapies, initial RNAi research breakthroughs, the advancement of oligonucleotide synthesis techniques, a growing demand for targeted therapeutics, and investments in biotech research.

The antisense & rnai therapeutics market is projected to experience swift expansion in the coming years, anticipated to reach a valuation of $3.53 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 12.9%. Key drivers for this growth during the forecast period include progress in delivery technologies, the broadening scope of precision medicine, the incorporation of AI in drug discovery, a rise in RNAi-based clinical trials, and increased healthcare investments within emerging markets. Significant trends expected in the same period encompass targeted gene silencing, innovative delivery mechanisms, personalized therapeutic approaches, techniques for nucleic acid stabilization, and ongoing regulatory and clinical advancements.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3389&type=smp

Which Drivers Are Impacting Market Performance In The Antisense & RNAi Therapeutics Market?

The anticipated increase in the incidence of coronary artery diseases, neurodegenerative conditions, and infectious diseases is expected to fuel the need for the antisense & RNAi therapeutics market. Gene suppression methods, such as RNA interference and antisense oligonucleotides, offer treatment for various neurodegenerative ailments through the correction of mutant genes. For example, a report from the American Heart Association, a US-based organization, indicated that in January 2024, the age-adjusted mortality rate for cardiovascular diseases climbed to 233.3 per 100,000, signifying a 4.0% increase compared to the prior year. Consequently, the expanding occurrence of numerous neurodegenerative and infectious diseases is set to propel the expansion of the antisense & RNAi therapeutics market.

Which Segments Are Contributing To The Growth Of The Antisense & RNAi Therapeutics Market?

The antisense & rnai therapeutics market covered in this report is segmented –

1) By Technology: RNA Interference, Antisense RNA

2) By Route Of Administration: Intravenous Injections, Intra-dermal Injections, Other Delivery Methods

3) By Indication: Oncology, Cardiovascular Diseases (CVDs), Respiratory Disorders, Neurological Disorders, Infectious Diseases, Other Indications

Subsegments:

1) By RNA Interference (RNAi): Small Interfering RNA (siRNA), Short Hairpin RNA (shRNA), Dicer-substrate siRNA, MicroRNA (miRNA) Based Therapeutics

2) By Antisense RNA: Antisense Oligonucleotides (ASOs), Morpholino Oligomers, Locked Nucleic Acids (LNAs), Gapmer Antisense Oligonucleotides

What Long-Term Trends Are Expected To Shape The Future Of The Antisense & RNAi Therapeutics Market?

Leading companies operating within the antisense & RNAi therapeutics market are implementing strategic initiatives, such as collaborations and partnerships, to maintain their standing in the increasingly competitive landscape. Strategic collaboration is a business approach involving two or more entities working together to achieve a shared goal or objective. For instance, in January 2023, Orbit Discovery Limited, a US-based company providing services for peptide discovery, collaborated with SanegeneBio Inc., a UK-based firm focused on developing novel RNAi-based medicines. This partnership aims to identify tissue-specific delivery methods for RNA therapeutics to enable efficient gene knockdown, with the ultimate goal of developing a portfolio of advanced RNAi therapeutics. The collaboration includes hit identification and cell-based internalization studies, granting Sanegene the option to further develop the hits derived from these screening activities by leveraging Orbit’s proprietary technology for rapid peptide lead discovery. Orbit Discovery’s unique peptide display engine allows for the screening of large peptide libraries, contributing to faster discovery times for relevant peptide leads based on affinity and functional screens.

Who Are The Primary Competitors In The Global Antisense & RNAi Therapeutics Market?

Major companies operating in the antisense & rnai therapeutics market are Biogen Inc., Ionis Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Moderna Inc., Sanofi S.A., Dicerna Pharmaceuticals Inc., Arbutus Biopharma Corporation, Acuitas Therapeutics, Adhera Therapeutics Inc., EdiGene Inc., Sirnaomics Inc., Suzhou Ribo Life Science Co. Ltd, Biocon Limited, Quark Pharmaceuticals, GlaxoSmithKline Plc, Shanghai Junshi Biosciences Co. Ltd., AstraZeneca, Benitec Biopharma Limited, Silence Therapeutics, Dynacure, CN Bio Innovations, Sarepta Therapeutics, Mallinckrodt, Regeneron Pharmaceuticals Inc., Alcyone Lifesciences Inc., Bio-Path Holdings Inc, Calando Pharmaceuticals, Enzon Pharmaceuticals Inc, Celnova Pharma, Pfizer Inc., Taiba Pharma, Gen Ilaç ve Saglik Ürünleri A.S., Egypt Otsuka Pharmaceutical

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/antisense-and-rnai-therapeutics-global-market-report

Which Global Regions Are Shaping The Competitive Landscape Of The Antisense & RNAi Therapeutics Market?

North America was the largest region in the antisense & RNAi therapeutics market in 2025. The regions covered in the antisense & rnai therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Antisense & RNAi Therapeutics Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=3389&type=smp

Browse Through More Reports Similar to the Global Antisense & RNAi Therapeutics Market 2026, By The Business Research Company

Antisense And Rnai Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/antisense-and-rnai-therapeutics-global-market-report

Rna Targeting Small Molecules Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/rna-targeting-small-molecules-therapeutics-global-market-report

Mrna Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/mrna-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the antisense & rnai therapeutics market from 2025–2034 with trusted insights from The Business Research Company

What Is The Present Size Of The Antisense & RNAi Therapeutics Market And What Value Is Projected For 2029?

The antisense & RNAi therapeutics market has experienced substantial expansion in recent years. Its value is projected to grow from $1.75 billion in 2024 to $1.93 billion in 2025, at a compound annual growth rate (CAGR) of 10.2%. Factors contributing to this historical growth include an increase in financial backing, progress in technologies, a rise in healthcare spending, the rapid aging of the population, and economic prosperity within developing markets.

The antisense & RNAi therapeutics market size is anticipated to undergo rapid expansion in the coming years. It is projected to grow to $3.11 billion in 2029, achieving a compound annual growth rate (CAGR) of 12.8%. This growth during the forecast period can be attributed to factors such as improved healthcare accessibility, the rising incidence of cancer, and an increased demand for antisense and RNAi therapeutics, partly influenced by COVID-19. Major trends expected in this period include focused efforts on the research and development of RNA therapeutics for orphan diseases, the adoption of nanoparticles, the advancement of new and enhanced antisense and RNAi therapeutics, and collaborations with other companies for product innovation and revenue generation.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3389&type=smp

What Factors Are Boosting The Antisense & RNAi Therapeutics Market?

The increasing occurrence of coronary artery diseases, neurodegenerative disorders, and infectious diseases is anticipated to boost the demand for the antisense & RNAi therapeutics market. Gene suppression approaches, including RNA interference and antisense oligonucleotides, are employed for the treatment of various neurodegenerative conditions by correcting mutant genes. For instance, in January 2024, according to a report from the American Heart Association, a US-based organization, the age-adjusted death rate from cardiovascular diseases climbed to 233.3 per 100,000, representing a 4.0% rise from the previous year. Consequently, the expanding prevalence of several neurodegenerative diseases and infectious diseases is expected to propel the growth of the antisense & RNAi therapeutics market.

What Are The Core Segmentation Criteria In The Antisense & RNAi Therapeutics Market?

The antisense & rnai therapeutics market covered in this report is segmented –

1) By Technology: RNA Interference, Antisense RNA

2) By Route Of Administration: Intravenous Injections, Intra-dermal Injections, Other Delivery Methods

3) By Indication: Oncology, Cardiovascular Diseases (CVDs), Respiratory Disorders, Neurological Disorders, Infectious Diseases, Other Indications

Subsegments:

1) By RNA Interference (RNAi): Small Interfering RNA (siRNA), Short Hairpin RNA (shRNA), Dicer-substrate siRNA, MicroRNA (miRNA) Based Therapeutics

2) By Antisense RNA: Antisense Oligonucleotides (ASOs), Morpholino Oligomers, Locked Nucleic Acids (LNAs), Gapmer Antisense Oligonucleotides

Which Emerging Trends Are Reshaping The Antisense & RNAi Therapeutics Market Landscape?

Companies operating within the antisense & RNAi therapeutics market are undertaking strategic initiatives, including collaborations and partnerships, to sustain themselves in the increasingly competitive environment. Strategic collaboration is a business strategy where two or more companies work together to achieve a common objective. For instance, in January 2023, Orbit Discovery Limited, a US-based company providing services for peptide discovery, partnered with SanegeneBio Inc., a UK-based company involved in developing novel RNAi-based medicines. This collaboration aimed to identify tissue-specific delivery methods for RNA therapeutics to achieve efficient gene knockdown, with the goal of developing an advanced RNAi therapeutics portfolio. The partnership encompasses hit identification and cell-based internalization studies, granting Sanegene the option to further develop the hits derived from the screening activities by utilizing Orbit’s proprietary technology for rapid peptide lead discovery. Orbit Discovery’s unique peptide display engine facilitates the screening of large peptide libraries, enabling faster discovery times for relevant peptide leads based on affinity and functional screens.

Which Players Are Shaping The Competitive Landscape Of The Antisense & RNAi TherapeuticsXX Market?

Major companies operating in the antisense & RNAi therapeutics market include Biogen Inc., Ionis Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Moderna Inc., Sanofi S.A., Dicerna Pharmaceuticals Inc., Arbutus Biopharma Corporation, Acuitas Therapeutics, Adhera Therapeutics Inc., EdiGene Inc., Sirnaomics Inc., Suzhou Ribo Life Science Co. Ltd, Biocon Limited, Quark Pharmaceuticals, GlaxoSmithKline Plc, Shanghai Junshi Biosciences Co. Ltd., AstraZeneca, Benitec Biopharma Limited, Silence Therapeutics, Dynacure, CN Bio Innovations, Sarepta Therapeutics, Mallinckrodt, Regeneron Pharmaceuticals Inc., Alcyone Lifesciences Inc., Bio-Path Holdings Inc, Calando Pharmaceuticals, Enzon Pharmaceuticals Inc, Celnova Pharma, Pfizer Inc., Taiba Pharma, Gen Ilaç ve Saglik Ürünleri A.S., Egypt Otsuka Pharmaceutical

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/antisense-and-rnai-therapeutics-global-market-report

What Regional Trends Are Shaping Growth In The Antisense & RNAi Therapeutics Market?

North America was the largest region in the antisense & RNAi therapeutics market in 2024. The regions covered in the antisense & RNAi therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=3389&type=smp

Browse Through More Reports Similar to the Global Antisense & RNAi Therapeutics Market 2025, By The Business Research Company

Anti Hypertensive Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/anti-hypertensive-drugs-global-market-report

Pharmaceutical Api Manufacturing Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/pharmaceutical-api-manufacturing-global-market-report

Microbiome Therapeutics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/microbiome-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim 20% Off Global Market Reports With Code ONLINE20 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

How Big Is The Antisense & RNAi Therapeutics Market Today And What Is Its Future Size?

The market for antisense & RNAi therapeutics has seen substantial growth in the past few years. Its size is projected to increase from $1.75 billion in 2024 to $1.93 billion in 2025, with a compound annual growth rate (CAGR) of 10.2%. Several factors have propelled the growth during the historic period, such as increased funding, technological advancements, escalated healthcare spending, a surge in the aging population, and economic expansion in emerging markets.

The market size of antisense & RNAi therapeutics is projected to experience a fast-paced expansion in the forthcoming years, with an estimation to reach “$3.11 billion in 2029, recording a compound annual growth rate (CAGR) of 12.8%. The anticipated growth during the forecasting timeline can be connected to the broader healthcare accessibility, escalating cases of cancer, and growing demand for antisense and RNAi therapeutics in light of the COVID-19. Key trends set to shape the forecast period encompass concentrated endeavors towards R&D of RNA therapeutics targeting rare diseases, incorporation of nanoparticles, evolution of advanced antisense and RNAi therapeutics, and partnerships with other firms for product ingenuity and revenue growth.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3389&type=smp

What Core Drivers Are Expected To Influence The Antisense & RNAi Therapeutics Market?

The antisense & RNAi therapeutics market is anticipated to grow due to the increasing incidences of coronary artery diseases, neurodegenerative disorders, and infectious diseases. Gene suppression methods such as RNA interference and antisense oligonucleotides are employed to treat various neurodegenerative conditions by correcting defective genes. To illustrate, a report released by the American Heart Association, a U.S. based entity, in January 2024 revealed that the age-adjusted death rate from cardiovascular diseases climbed to 233.3 per 100,000—marking a 4.0% increase compared to the prior year. Therefore, the escalating rates of numerous neurodegenerative and infectious diseases are likely to propel the expansion of the antisense & RNAi therapeutics market.

Which Segmentation Factors Are Critical In The Antisense & RNAi Therapeutics Market Analysis?

The antisense & rnai therapeutics market covered in this report is segmented –

1) By Technology: RNA Interference, Antisense RNA

2) By Route Of Administration: Intravenous Injections, Intra-dermal Injections, Other Delivery Methods

3) By Indication: Oncology, Cardiovascular Diseases (CVDs), Respiratory Disorders, Neurological Disorders, Infectious Diseases, Other Indications

Subsegments:

1) By RNA Interference (RNAi): Small Interfering RNA (siRNA), Short Hairpin RNA (shRNA), Dicer-substrate siRNA, MicroRNA (miRNA) Based Therapeutics

2) By Antisense RNA: Antisense Oligonucleotides (ASOs), Morpholino Oligomers, Locked Nucleic Acids (LNAs), Gapmer Antisense Oligonucleotides

What Are The Dominant Trends Currently Seen In The Antisense & RNAi Therapeutics Market?

Prominent businesses in the antisense & RNAi therapeutics market are employing strategic initiatives such as collaborations and partnerships to maintain their position in this fiercely competitive marketplace. The manoeuvre of strategic collaboration involves two or more companies joining forces to realise a shared purpose or goal. As an example, in January 2023, Orbit Discovery Limited, a US-based business that offers peptide discovery services, allied with SanegeneBio Inc., a UK-based company engaged in developing innovative RNAi-based medicines, for the identification of tissue-specific RNA therapeutic delivery for effective gene knockdown with the joint aim to expand their advanced RNAi therapeutics portfolio. This agreement includes the identification of probable hits and cell-based absorption studies, where Sanegene can opt to refine the potential hits resulting from the screening procedures, utilizing Orbit’s proprietary technology for prompt peptide lead discovery. The unique peptide display engine of Orbit Discovery facilitates the examination of extensive peptide libraries, resulting in quicker identification of pertinent peptide leads through affinity and functional screening.

Which Players Are Shaping The Competitive Landscape Of The Antisense & RNAi Therapeutics Market?

Major companies operating in the antisense & RNAi therapeutics market include Biogen Inc., Ionis Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Moderna Inc., Sanofi S.A., Dicerna Pharmaceuticals Inc., Arbutus Biopharma Corporation, Acuitas Therapeutics, Adhera Therapeutics Inc., EdiGene Inc., Sirnaomics Inc., Suzhou Ribo Life Science Co. Ltd, Biocon Limited, Quark Pharmaceuticals, GlaxoSmithKline Plc, Shanghai Junshi Biosciences Co. Ltd., AstraZeneca, Benitec Biopharma Limited, Silence Therapeutics, Dynacure, CN Bio Innovations, Sarepta Therapeutics, Mallinckrodt, Regeneron Pharmaceuticals Inc., Alcyone Lifesciences Inc., Bio-Path Holdings Inc, Calando Pharmaceuticals, Enzon Pharmaceuticals Inc, Celnova Pharma, Pfizer Inc., Taiba Pharma, Gen Ilaç ve Saglik Ürünleri A.S., Egypt Otsuka Pharmaceutical

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/antisense-and-rnai-therapeutics-global-market-report

Which Region Is Likely To Register The Fastest Growth In The Antisense & RNAi Therapeutics Market?

North America was the largest region in the antisense & RNAi therapeutics market in 2024. The regions covered in the antisense & RNAi therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=3389&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Outlook for the Antisense & RNAi Therapeutics Market Heading Into 2029?

In recent years, the antisense & RNAi therapeutics market has seen significant expansion. The market, valued at $1.75 billion in 2024, is expected to grow to $1.93 billion in 2025 with a compound annual growth rate (CAGR) of 10.2%. Several factors contribute to this growth during the historical period, including increased funding, advancements in technology, elevated healthcare spending, a quickly aging population, and economic growth in developing markets.

The market for antisense and RNAi therapeutics is projected to experience fast-paced expansion in the coming years, with expected growth to “$3.11 billion in 2029 at a compound annual growth rate (CAGR) of 12.8%.” This anticipated surge during the forecast period could be linked to enhanced healthcare accessibility, growing cancer prevalence and a spike in the requirement for antisense and RNAi therapeutics due to the COVID-19 pandemic. Key trends throughout this period look set to involve concentrated research and development efforts for RNA therapeutic treatments for rare diseases, the employment of nanoparticles, the creation of advanced and more effective antisense and RNAi therapeutics, and partnerships with other firms for product innovation and revenue generation.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3389&type=smp

Which Factors Are Pushing The Antisense & RNAi Therapeutics Market Forward?

The surging incidence of maladies such as coronary artery diseases, neurodegenerative disorders, and infectious diseases is predicted to spur the demand for the antisense & RNAi therapeutics market. Treatment strategies that suppress genes, such as RNA interference and antisense oligonucleotides, are employed to treat numerous neurodegenerative disorders by mending defective genes. For example, a report from the American Heart Association, an organization based in the US, stated that in January 2024, the age-adjusted mortality rate from cardiovascular diseases rose to 233.3 per 100,000, a 4.0% increase from the preceding year. Consequently, the rising incidence of multiple neurodegenerative and infectious diseases is anticipated to be a key driver of growth for the antisense & RNAi therapeutics market.

The antisense & rnai therapeutics market covered in this report is segmented –

1) By Technology: RNA Interference, Antisense RNA

2) By Route Of Administration: Intravenous Injections, Intra-dermal Injections, Other Delivery Methods

3) By Indication: Oncology, Cardiovascular Diseases (CVDs), Respiratory Disorders, Neurological Disorders, Infectious Diseases, Other Indications

Subsegments:

1) By RNA Interference (RNAi): Small Interfering RNA (siRNA), Short Hairpin RNA (shRNA), Dicer-substrate siRNA, MicroRNA (miRNA) Based Therapeutics

2) By Antisense RNA: Antisense Oligonucleotides (ASOs), Morpholino Oligomers, Locked Nucleic Acids (LNAs), Gapmer Antisense Oligonucleotides

What Are The Leading Trends And Opportunities In The Antisense & RNAi Therapeutics Sector?

Leading businesses in the antisense & RNAi therapeutics market are employing strategic actions like collaborations and partnerships to maintain their competitiveness in the escalating market arena. Such a strategic partnership typically involves multiple firms cooperating to fulfil a shared goal or objective. For instance, in January 2023, Orbit Discovery Limited, a company from the US that provides services for peptide discovery, formed an alliance with SanegeneBio Inc., a UK-based firm developing innovative RNAi-based medicines. This partnership is geared towards developing advanced RNAi therapeutics, with a specific focus on identifying tissue-specific delivery of RNA therapeutics for more efficient gene knockdown. The partnership extends to hit identification and cell-based internalization research, with SanegeneBio having the choice to advance the development of the hits that come from the screening phases, using Orbit’s original rapid peptide lead discovering technology. Orbit Discovery’s one-of-a-kind peptide display system facilitates the screening of significant peptide libraries, resulting in faster identification of relevant peptide leads via affinity and functional screens.

Which Organizations Are Driving Progress In The Antisense & RNAi Therapeutics Industry?

Major companies operating in the antisense & RNAi therapeutics market include Biogen Inc., Ionis Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Moderna Inc., Sanofi S.A., Dicerna Pharmaceuticals Inc., Arbutus Biopharma Corporation, Acuitas Therapeutics, Adhera Therapeutics Inc., EdiGene Inc., Sirnaomics Inc., Suzhou Ribo Life Science Co. Ltd, Biocon Limited, Quark Pharmaceuticals, GlaxoSmithKline Plc, Shanghai Junshi Biosciences Co. Ltd., AstraZeneca, Benitec Biopharma Limited, Silence Therapeutics, Dynacure, CN Bio Innovations, Sarepta Therapeutics, Mallinckrodt, Regeneron Pharmaceuticals Inc., Alcyone Lifesciences Inc., Bio-Path Holdings Inc, Calando Pharmaceuticals, Enzon Pharmaceuticals Inc, Celnova Pharma, Pfizer Inc., Taiba Pharma, Gen Ilaç ve Saglik Ürünleri A.S., Egypt Otsuka Pharmaceutical

https://www.thebusinessresearchcompany.com/report/antisense-and-rnai-therapeutics-global-market-report

Which Region Is Expected To Experience The Highest Growth In The Antisense & RNAi Therapeutics Industry?

North America was the largest region in the antisense & RNAi therapeutics market in 2024. The regions covered in the antisense & RNAi therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=3389&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model